• português (Brasil)
    • English
    • español
  • English 
    • Português (Brasil)
    • English
    • Español
  • Login
          AJUDA
Pesquisa
avançada
     
View Item 
  •   RIUFF
  • TEDE - Migração
  • TEDE sem arquivo
  • View Item
  •   RIUFF
  • TEDE - Migração
  • TEDE sem arquivo
  • View Item
JavaScript está desabilitado no seu navegador. Algumas funcionalidades deste site podem não funcionar.

Browse

All of DSpaceCommunities & CollectionsBy Issue DateAuthorsAdvisorsTitlesSubjectsDepartmentProgramTypeType of AccessThis CollectionBy Issue DateAuthorsAdvisorsTitlesSubjectsDepartmentProgramTypeType of Access

Statistics

View Usage Statistics

Collections
  • TEDE sem arquivo

Statistics
Metadata
Show full item record
AVALIAÇÃO DA PARCERIA ENTRE INDÚSTRIA FARMACÊUTICA E UNIVERSIDADE COMO ESTRATÉGIA PARA A INOVAÇÃO DE MEDICAMENTOS NO BRASIL
Abstract
Innovation is the keyword for the pharmaceutical sector. Strategically, innovation in product is pivotal for companies to continue to be competitive in this sector, which is deemed as essentially science-based. Brazil is one of the greatest markets in the world in medicine sales, but presents little innovation, increasing expenses with health in the country. Due to the high risks and costs inherent to this kind of innovation, countries considered innovation-driven, such as the USA, commonly establish partnerships between pharmaceutical companies and universities for achieving new therapeutic options; in Brazil, this strategy is little used, though some actions in this field have already brought good results in the area. Deemed as a milestone, the Innovation Law, together with other initiatives of economic subvention, is seen by the Ministry of Health as the great strategic promise in the field of drugs and medicines. Through exploratory research, the current study investigated the impact of the Innovation Act in the sector and how pharmaceutical industries evaluate universities as strategic partners for medicine research and development. Through questionnaires sent to private pharmaceutical companies and to Núcleos de Inovação Tecnológica (Centers for Technological Innovation) (NITs), the results enabled to ponder about the relation among industry, government, and university in the promotion of medicine innovation in Brazil. Aspects related to the management model to be stimulated, the influence of governmental initiatives, criteria considered by companies for creating these partnerships, as well as activities that must be developed by NITs for the success of this type of alliance, are discussed in the present survey.
[Texto sem Formatação]
Document type
Dissertação
Format
application/pdf
Subject(s)
Estratégia empresarial
Inovação tecnológica
Indústria farmacêutica
Medicamento
Brasil
Estratégia competitiva
Parceria universidade-indústria farmacêutica
Hélice-tríplice
Lei da Inovação
Governo
Competitive strategy innovation
University pharmaceutical industry partnership
Triple helix
Innovation
Innovation act
Medicine
Governanment
CNPQ::ENGENHARIAS::ENGENHARIA DE PRODUCAO
 
URI
https://app.uff.br/riuff/handle/1/19396
License Term
CC-BY-SA
DSpace
DSpace
DSpace
DSpace
DSpace
DSpace

  Contact Us

 Fale com um bibliotecário

DSpace  Siga-nos no Instagram